Large pharmaceutical companies remain key players in the healthcare ecosystem, often providing the resources, global reach, and expertise needed to bring breakthrough innovations to market. For early-stage companies, forging the right partnerships with big pharma can validate their science, accelerate product development, and unlock access to broader commercialization pathways.

This 50-minute panel will highlight how startups and established pharma companies collaborate across licensing, R&D partnerships, co-development deals, and strategic investments. Panelists will share insights on what pharma seeks in potential partners, how these relationships are structured, and the role of corporate venture arms in supporting innovation. Learn how to navigate these partnerships to create win–win opportunities that drive therapies forward to patients worldwide.

Angels and family offices play a vital role in the life science and healthcare funding landscape, often providing the first capital that enables an entrepreneur to advance their vision. With greater flexibility and a longer-term investment horizon than traditional venture firms, these investors can offer unique advantages to early-stage companies.

This panel brings together active angels and family office investors to discuss how they evaluate opportunities, what differentiates their approach to supporting founders, and how they think about portfolio diversification in healthcare. Panelists will explore investment motivations, decision-making processes, and ways they add value beyond capital. Hear directly from investors whose patient, flexible funding strategies can help lay the foundation for breakthrough healthcare innovations.

Medical devices and diagnostics remain cornerstones of healthcare innovation, driving earlier detection, more accurate diagnosis, and better patient management. From Class I to Class III devices and from point-of-care tests to complex diagnostics, companies are pushing boundaries in usability, cost-effectiveness, and clinical impact.

This 50-minute panel convenes investors and strategics with deep expertise in devices and diagnostics. Panelists will discuss what they look for in new technologies, how regulatory and reimbursement pathways influence their investment theses, and the emerging trends shaping the field. Join the conversation to understand where capital is flowing and how innovators can position their products to improve patient outcomes and meet unmet clinical needs.

Digital health and artificial intelligence are reshaping the healthcare ecosystem, offering solutions that enhance patient engagement, reduce costs, and improve clinical decision-making. Investors are increasingly drawn to platforms that leverage data, predictive analytics, and scalable delivery models to create impact at population scale.

This panel brings together leading investors and experts in digital health and AI to discuss what excites them in this rapidly evolving space. Topics will include data privacy, integration into existing health systems, and pathways to commercialization. Panelists will share how they evaluate business models, manage regulatory considerations, and identify companies capable of delivering both strong returns and meaningful improvements in care delivery.

Europe, and the UK in particular, continues to be a hub of healthcare and life science innovation. From strong academic research institutions to growing clusters of biotech and medtech startups, the region is attracting global capital and forging cross-border partnerships. For investors and entrepreneurs, understanding this ecosystem is critical to tapping into its unique opportunities.

In this 50-minute panel, investors and ecosystem leaders from the UK and Europe will share perspectives on fundraising, regulatory environments, and collaboration opportunities. Learn how European startups are scaling internationally, how regional policies shape innovation, and where global investors are finding compelling opportunities across the continent.

The earliest stages of therapeutic development demand vision, conviction, and capital. Investors in early-stage therapeutics face unique challenges: high scientific risk, long timelines, and the need to carefully validate mechanisms of action before reaching clinical milestones. Yet, it is precisely at this stage where transformative medicines are born.
This 50-minute panel convenes investors and fund managers focused on early-stage drug development to explore how they evaluate novel modalities, indications, and platforms. Panelists will share perspectives on building strong scientific foundations, partnering with academic institutions, navigating regulatory pathways, and supporting teams as they transition from preclinical to clinical development. Attendees will gain insights into what it takes to secure investment, structure early deals, and build the right syndicates to carry a therapeutic program toward clinical proof-of-concept.

Seed funds provide the critical early-stage capital that helps transform bold scientific ideas into viable healthcare ventures. By investing at the riskiest point in a company’s journey, seed funds fuel innovation that may not yet attract larger institutional capital, but has the potential to create transformative impact.

This 50-minute panel brings together managers of seed-stage funds to discuss how they identify promising founders and technologies, structure early deals, and support portfolio companies through the difficult first stages of growth. Panelists will also share perspectives on syndication strategies, bridging to Series A, and how they add value beyond financing. Learn what it takes to secure early backing and build momentum from the very start.